Purpose of review 

This review analyzes currently available commercial transcatheter aortic valve replacement (TAVR) valves as well as valves in investigational status and those in preclinical testing. The design features and clinical outcomes of the Edwards SAPIEN S3 and Medtronic Evolut PRO+ are described and compared with highlight clinical circumstances where one may be favoured over the other.

Recent findings 

Multiple randomized and nonrandomized trials have compared commercial and investigational TAVR valves. The results of these are summarized and discussed within this review with a focus on how the SAPIEN S3 and Evolut PRO+ both compare to each other as well as various valves in different investigational stages.

Summary 

TAVR is an innovative and ground-breaking technology that will forever have revolutionized the management of aortic stenosis. Though the technology and valves themselves have come a long way, further developments are necessary if we are to continue to expand its indications and achieve a safer perioperative experience with more durable valves.

中文翻译：

---

当前和未来的经导管主动脉瓣置换瓣膜

审查目的 

本综述分析了目前可用的商业经导管主动脉瓣置换 (TAVR) 瓣膜以及处于研究状态和临床前测试状态的瓣膜。描述了 Edwards SAPIEN S3 和 Medtronic Evolut PRO+ 的设计特点和临床结果，并与其中一种可能优于另一种的突出临床情况进行了比较。

最近的发现 

多项随机和非随机试验对商业和研究性 TAVR 瓣膜进行了比较。本次审查对这些结果进行了总结和讨论，重点是 SAPIEN S3 和 Evolut PRO+ 之间的比较以及不同研究阶段的各种阀门的比较。

概括 

TAVR 是一项创新的突破性技术，将永远彻底改变主动脉瓣狭窄的治疗。尽管技术和瓣膜本身已经取得了长足的进步，但如果我们要继续扩大其适应症并通过更耐用的瓣膜实现更安全的围手术期体验，则需要进一步的发展。